Skip to main content
Spexis AG logo

Spexis AG — Investor Relations & Filings

Ticker · SPEX ISIN · CH0106213793 LEI · 391200S8HJE1I96FIG04 SW Manufacturing
Open in API
Filings indexed 194 across all filing types
Latest filing 2024-04-17 Legal Proceedings Report
Country CH Switzerland
Listing SW SPEX

About Spexis AG

https://www.polyphor.com/

Spexis AG is a clinical-stage biopharmaceutical company focused on discovering and developing therapeutics for rare diseases and oncology. The company leverages its expertise in macrocycle technology to create novel drug candidates designed to address high unmet medical needs. Its pipeline is advanced through a strategy that includes in-house discovery, development, in-licensing, and the acquisition of promising molecules. The primary therapeutic areas of interest include rare diseases and cancer, with an additional focus on antimicrobial resistance.

Recent filings

Filing Released Lang Actions
Spexis announces extension of moratorium, receipt of an additional payment related to the sale of a preclinical antibiotics program and reversion of the lonodelestat license from Santhera
Legal Proceedings Report Classification · 99% confidence The document is explicitly titled 'Ad hoc announcement pursuant to Art. 53 LR' and details several significant, non-scheduled corporate events: extension of a provisional moratorium, receipt of an additional payment from an asset sale, and the reversion of a license agreement. This type of immediate, material disclosure, often mandated by listing rules (like the SIX Listing Rules, indicated by 'Art. 53 LR'), is characteristic of a general regulatory announcement that doesn't fit neatly into specific financial reporting categories (like 10-K, ER, or IR). Since it is a material, unscheduled update, it fits best under the general 'Regulatory Filings' category, which serves as a fallback for such announcements not covered by more specific codes like DIV, CAP, or MANG. It is not a formal Earnings Release (ER) or Interim Report (IR), nor is it a presentation (IP) or a transcript (CT).
2024-04-17 English
Spexis announces closing of sale of preclinical antibiotics program to Basilea
M&A Activity Classification · 99% confidence The document is explicitly labeled as an 'Ad-hoc announcement pursuant to Art. 53 LR' and details a specific corporate transaction: the closing of the sale of a preclinical antibiotics program from Spexis to Basilea. This type of announcement, which reports on a significant, non-routine corporate event (like an asset sale or major agreement closing) outside of standard periodic financial reporting (10-K, IR), typically falls under general regulatory announcements or news releases. Since it is not a standard financial report (10-K, IR, ER, MRQ), nor a management change (MANG), nor a capital change (CAP/SHA), nor a proxy/dividend notice, the most appropriate classification is the general regulatory filing/announcement category, RNS (Regulatory Filings), as it is a mandatory disclosure of material, non-public information.
2024-02-08 English
Spexis announces closing of sale of preclinical antibiotics program to Basilea
M&A Activity Classification · 99% confidence The document is titled 'Ad hoc announcement pursuant to Art. 53 LR' and details the closing of an asset purchase agreement between Spexis and Basilea. It is a formal, time-sensitive disclosure of a significant corporate event (divestiture of a preclinical program). This type of announcement, which is not a full financial report (like 10-K or IR), a management discussion (MDA), or a specific regulatory filing like DIRS or DIV, falls best under the general category for regulatory disclosures that don't fit elsewhere, especially since it is explicitly labeled as an 'Ad hoc announcement'. Given the options, 'Regulatory Filings' (RNS) is the most appropriate fallback for a general, non-standardized corporate disclosure that is mandatory under listing rules (LR) but doesn't match the specific definitions like ER, CT, or CAP. It is not an announcement *of* a report, but the report *is* the announcement itself.
2024-02-08 English
Spexis announces sale of preclinical antibiotics program to Basilea
Regulatory Filings Classification · 100% confidence The document is titled 'News Details' and is released as an 'Ad-hoc announcement pursuant to Art. 53 LR' on January 15, 2024. It details a specific corporate action: the sale of a preclinical antibiotics program from Spexis to Basilea. This type of announcement, which reports on a significant, non-routine corporate event (like an asset sale or major transaction) outside of standard periodic reporting cycles (like 10-K or IR), is typically classified as a general regulatory announcement or 'Ad-hoc' filing. Since the provided categories do not have a specific 'Ad-hoc' code, and this is not a standard financial report (10-K, IR, ER), nor a management change (MANG), nor a financing event (CAP) in the sense of raising capital for the company itself, the most appropriate fallback category is 'Regulatory Filings' (RNS), which covers general regulatory announcements that don't fit elsewhere. The document length is substantial (9051 chars), so it is the report itself, not just an announcement of a report (RPA).
2024-01-15 English
Spexis announces sale of preclinical antibiotics program to Basilea
Regulatory Filings Classification · 95% confidence The document is titled 'Ad hoc announcement pursuant to Art. 53 LR' and details a specific corporate transaction: the sale of a preclinical antibiotics program from Spexis AG to Basilea Pharmaceutica Ltd. This type of announcement, disclosing material, non-public information outside of routine periodic filings, is characteristic of a general regulatory disclosure or press release concerning a significant event (like a disposal/asset sale). Since it is not a formal 10-K, 10-Q (IR), Earnings Release (ER), or a specific shareholder vote result (DVA), the most appropriate classification is the general regulatory announcement category, RNS (Regulatory Filings), as it serves as an immediate disclosure mechanism for material events.
2024-01-15 English
Spexis is Granted Debt-Restructuring Moratorium
Legal Proceedings Report Classification · 99% confidence The document is a short press release dated December 5, 2023, labeled as 'Ad-hoc' and released pursuant to 'Art. 53 LR'. It announces a specific corporate event: the granting of a debt-restructuring moratorium to Spexis AG. This type of announcement, which details a significant, non-financial operational or legal event outside of standard periodic reporting (like 10-K or IR), often falls under general regulatory disclosure or miscellaneous news. Since it is not an earnings release (ER), a capital change (CAP/SHA), a director dealing (DIRS), or a specific legal report (LTR), and it is a direct announcement rather than a report itself (Rule 2 applies, length is short), the most appropriate general category for an ad-hoc regulatory disclosure that doesn't fit elsewhere is Regulatory Filings (RNS).
2023-12-05 English

Browse filings by year

10 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.